Selank: The Russian Anti-Anxiety Peptide That Works Like a Benzo — Without the Downsides

The short version

Selank is a synthetic heptapeptide approved in Russia since 2009 for generalized anxiety disorder and neurasthenia. It’s been OTC (no prescription needed) since 2017.
In a head-to-head trial against medazepam (a benzodiazepine), Selank showed comparable anxiety reduction — plus anti-fatigue and mild cognitive benefits that the benzo didn’t have. No sedation, no dependence, no withdrawal.
40% of patients are “rapid responders” — anxiety scores dropped from 20.3 to 7.0 on the Hamilton scale within 1-3 days. The other 60% need the full 14-day course.
Selank is built from tuftsin, a natural immune peptide, which is why it has a dual personality: anxiolytic AND immunomodulatory. It modifies expression of at least 34 inflammation genes and shows antiviral activity against influenza A.
Intranasal bioavailability is 92.8% — detectable in plasma within 30 seconds of administration. Exceptionally high for a peptide.
N-Acetyl Selank Amidate (the popular modified variant) has zero published clinical studies. All evidence comes from unmodified Selank.
Not FDA-approved. Removed from FDA Category 2 in September 2024 and referred to PCAC for review.

The anxiety problem nobody talks about

Here’s the situation millions of people are stuck in.

You have anxiety. Not the “I’m nervous about a presentation” kind — the persistent, background-static kind that makes everything harder than it should be. Your options are:

SSRIs — take weeks to work, come with sexual side effects, and getting off them can be its own nightmare.

Benzodiazepines — work fast, work well, and will absolutely wreck you if you take them regularly. Tolerance, dependence, withdrawal seizures. Your doctor will prescribe them reluctantly, if at all.

Buspirone — takes weeks, modest effects, but at least it won’t hook you.

Supplements — L-theanine, ashwagandha, magnesium. Gentle. Sometimes enough. Often not.

Now imagine a compound that reduces anxiety as effectively as a benzodiazepine, kicks in within days for many people, doesn’t cause sedation, doesn’t impair cognition, doesn’t create dependence, and actually improves your focus and energy levels at the same time.

That compound exists. It’s been approved in Russia for 16 years. It’s called Selank.

The catch — because there’s always a catch — is that the clinical evidence, while genuinely compelling, comes almost entirely from Russian institutions with limited sample sizes and no independent Western replication. So let’s look at exactly what we know and what we don’t.

What Selank is — and why it’s built from an immune peptide

Selank’s origin story starts in an unexpected place: your immune system.

In 1970, a scientist named Victor Najjar discovered a small peptide called tuftsin — a four-amino-acid fragment (Thr-Lys-Pro-Arg) naturally produced by your spleen. Tuftsin’s job is immunological: it stimulates phagocytosis (the process where immune cells engulf and destroy pathogens), activates natural killer cells, and modulates cytokine production.

Two decades later, at the Institute of Molecular Genetics in Moscow, the same team that created Semax — Igor Ashmarin and Nikolay Myasoedov — asked an interesting question: what if they could stabilize tuftsin for use as a drug? Raw tuftsin breaks down in the blood within minutes. But they’d already solved this problem with Semax by adding a Pro-Gly-Pro tripeptide tail.

So they did the same thing. They took tuftsin (Thr-Lys-Pro-Arg) and attached the PGP tail, creating a seven-amino-acid peptide: Thr-Lys-Pro-Arg-Pro-Gly-Pro.

They named it Selank.

What they discovered surprised them. The compound retained tuftsin’s immune-modulating properties — but it also had powerful anxiolytic and nootropic effects that tuftsin alone didn’t have. The PGP tail wasn’t just a stabilizer. It contributed its own neurological activity.

This dual identity — anxiety drug built from an immune peptide — is what makes Selank genuinely unique. No other anxiolytic on the market works through immunomodulatory pathways. And it goes a long way toward explaining why Selank’s effects feel different from anything else people have tried.

How it works

Selank’s mechanism isn’t a single clean pathway. It operates through at least seven documented systems, which is part of why it has such a broad effect profile.

1. GABA system modulation

This is the primary anxiolytic mechanism. A genome-wide study found that Selank altered expression of 45 GABA-related genes at 1 hour and 22 genes at 3 hours after administration — including genes for GABA-A receptor subunits, GABA transporters, and GABA synthesis enzymes [Volkova et al., 2016, PMID: 26924987].

But here’s the key difference from benzodiazepines: benzos bind directly to GABA-A receptors and force them open. Selank modulates the entire GABAergic system at the gene expression level — changing how many receptors are built, how GABA is synthesized, and how it’s transported. The effect is slower to develop but more physiologically balanced. It’s the difference between turning up the volume knob (benzos) and upgrading the entire sound system (Selank).

2. Enkephalin preservation

Your body produces its own anti-anxiety molecules called enkephalins — endogenous opioid peptides that reduce pain and anxiety. The problem is they’re rapidly broken down by enzymes. Selank inhibits these enkephalin-degrading enzymes with an IC50 of 15-20 μM [Kost et al., 2001, PMID: 11443939], effectively extending the life of your body’s own calming molecules.

3. Serotonin and norepinephrine normalization

In stressed animals, Selank normalized serotonin metabolism and norepinephrine levels that had been disrupted by chronic stress — not by flooding the system with more serotonin (like SSRIs), but by restoring the natural balance [Narkevich et al., 2008, PMID: 19093364].

4. BDNF upregulation

Like its sibling Semax, Selank increases BDNF mRNA in the hippocampus, with effects peaking at about 90 minutes after administration [Inozemtseva et al., 2008, PMID: 18841804]. This likely contributes to the nootropic effects that accompany the anxiolysis.

5. Immune modulation

This is the tuftsin heritage. Selank modifies the expression of at least 34 inflammation-related genes in the spleen. It normalizes stress-disrupted cytokine profiles — IL-1β, IL-6, TNF-α, and TGF-β1 all returned to control values in stressed animals. Most remarkably, Selank showed antiviral activity, with one study reporting complete suppression of influenza A virus reproduction when used preventively.

6. Dopamine D5 receptor activation

Selank selectively upregulates the Drd5 (dopamine D5 receptor) gene at 3 hours — a receptor involved in long-term potentiation and memory formation. This effect is specific to Selank and was not observed with Semax in the same study.

7. NMDA glycine site interaction

Recent research suggests Selank interacts with the glycine binding site on NMDA receptors [Vasil’eva et al., 2023], adding another dimension to its cognitive effects.

The net result of all seven pathways: anxiety goes down, focus goes up, immune function improves, and none of the cognitive blunting or sedation that defines most anxiolytics.

The clinical evidence

Head-to-head against a benzodiazepine (n=62)

The landmark Selank trial compared it directly to medazepam (a benzodiazepine) in 62 patients with generalized anxiety disorder and neurasthenia [Zozulya et al., 2008, PMID: 18454096].

30 patients received Selank (0.15% nasal drops)
32 patients received medazepam (a standard benzo)
Result: Anxiolytic effects were comparable between the two groups
Where Selank won: It additionally showed antiasthenic (anti-fatigue) and psychostimulant effects that the benzodiazepine did not produce
What Selank didn’t do: No sedation, no muscle relaxation, no tolerance, no withdrawal
The study concluded Selank had “pronounced anxiolytic potential” with a uniquely favorable side effect profile

The rapid responders (n=20)

A study of 20 patients with GAD (diagnosed by DSM-IV criteria) revealed a striking split in response patterns [European Psychiatry, 2012]:

40% were rapid responders: Hamilton Anxiety Rating Scale (HARS) scores dropped from 20.3 to 7.0 (p<0.01) within 1-3 days
60% were gradual responders: Reached HARS 6.2 by Day 14
Both groups achieved clinically meaningful anxiety reduction — the difference was speed of onset

For context, a HARS score of 20 is moderate anxiety. A score of 7 is essentially normal. Dropping that far in 1-3 days, without a benzodiazepine, is remarkable.

Selank vs. phenazepam (n=60)

Two studies by Medvedev et al. (2014-2015) compared Selank to phenazepam, a more potent benzodiazepine widely used in Russia [PMID: 25176261]:

Selank’s anxiolytic effect persisted for 1 week after discontinuation — suggesting it produces lasting changes rather than just masking symptoms
When Selank was combined with phenazepam, it enhanced the benzo’s therapeutic effects while reducing its side effects
This led the authors to suggest Selank could be used as a benzo-sparing agent

Post-COVID fatigue (n=64, 2024)

The most recent Selank clinical study examined patients with persistent fatigue after COVID-19 [Pogodina & Nikiforova, 2024]:

64 patients with post-COVID asthenia
Selank reduced fatigue severity and improved cognitive symptoms
This is notable because long COVID fatigue has proven extremely difficult to treat with existing medications

Adjustment disorder and PTSD (n=30)

A 2017 study by Verbenko and Shakina screened 577 patients and treated 30 with adjustment disorder/PTSD symptoms:

Significant improvements on PHQ (Patient Health Questionnaire)
Effects persisted at 4-week follow-up after treatment ended

Psychogenic overeating

An unexpected application: Selank reduced depression by 2.6-fold, anxiety by 3.1-fold, and produced an average weight loss of 2.3 kg in patients with psychogenic overeating [Verbenko & Fedorov, 2016]. The mechanism likely involves normalizing the stress-eating cycle through anxiety reduction.

fMRI brain imaging (n=52)

A 2020 fMRI study directly compared brain network changes from Selank, Semax, and placebo in 52 subjects [PMID: 32342318]. Selank produced distinct patterns of functional connectivity changes compared to both Semax and placebo, confirming that its effects are neurologically real and measurably different from its sister compound.

Selank + Semax: the most popular nootropic peptide stack

These two peptides were developed at the same institute, share the same PGP tail, and are designed to complement each other:

	Selank	Semax
Primary effect	Anxiolytic, calming	Cognitive activation, focus
BDNF	Moderate increase	Strong increase (1.4x protein, 3x mRNA)
Dopamine	D5 receptor (memory)	Potentiates dopaminergic circuits
GABA	45 gene expression changes	147% current augmentation
Serotonin	Normalizes under stress	180% turnover increase
Immune	Strong immunomodulation	Moderate (under ischemia)
Subjective	Calm clarity	Driven focus

The combination logic: Semax provides cognitive drive and BDNF-mediated neuroplasticity. Selank provides emotional stability and stress resilience. Together, you get focused productivity without the anxiety that often accompanies stimulation.

The honest caveat: No clinical study has ever tested the Semax + Selank combination. The rationale is pharmacologically sound — different primary mechanisms, complementary effects, same PGP backbone. Community experience is consistently positive. But “makes pharmacological sense and users like it” is not clinical evidence.

Practical advice from the community: Try each compound alone for at least a week before combining. This way you know what each one does for you individually. Common combined protocol: Semax in the morning for focus, Selank morning and early afternoon for sustained calm. Both intranasal.

N-Acetyl Selank Amidate — the evidence gap

The modified variant N-Acetyl Selank Amidate (NA-Selank) is widely marketed as a superior version with improved stability and blood-brain barrier penetration.

Here’s what the evidence says: nothing. Zero published clinical studies on NA-Selank. Zero preclinical studies. Every piece of evidence supporting Selank’s effects comes from the unmodified compound.

The chemical modifications (N-terminal acetylation + C-terminal amidation) are theoretically reasonable for improving peptide stability. But “theoretically reasonable” is not evidence. And as we noted in our Semax article, N-terminal acetylation of Semax was shown to abolish its copper-chelating neuroprotective mechanism. Whether a similar trade-off exists for Selank’s modifications is unknown — because nobody has studied it.

User reports on NA-Selank are mixed. Some prefer it. Others notice no difference from standard Selank. Without controlled data, these reports are impossible to interpret meaningfully.

Our recommendation: If you’re going to try Selank, start with the compound that was actually studied in clinical trials — standard Selank.

Safety

Selank’s safety profile across all published research is clean.

No serious adverse events have been reported in any clinical trial. Specifically:

No sedation (this is consistently highlighted as a key differentiator from benzos)
No tolerance development documented
No dependence
No withdrawal symptoms
No cognitive impairment — if anything, mild cognitive improvement
No mutagenic or teratogenic effects in preclinical testing
Effects persist 1+ weeks after discontinuation (suggesting lasting changes, not just symptom masking)

Reported side effects (rare and mild):

Nasal irritation with intranasal use
Occasional mild headache

From the Russian prescribing information:

Contraindicated in pregnancy and breastfeeding
No documented drug interactions — but caution warranted with MAOIs, stimulants, and SSRIs given the serotonergic and GABAergic mechanisms
Low toxicity classification

What we don’t have:

Western-standard long-term safety monitoring
Drug interaction studies with common Western psychiatric medications
Post-marketing pharmacovigilance data

The honest limitations

Sample sizes are small. The largest trial is n=62. Most are n=20-60. These are meaningful signals, not definitive proof.

No placebo-controlled trials for the primary anxiety indication. The GAD trial used an active comparator (medazepam), which is actually a harder test to pass than placebo — but the lack of a placebo arm means we can’t calculate absolute effect size.

All clinical data is Russian. Same institution, same research group, potential conflicts of interest. No independent Western replication. Russian Wikipedia classifies Selank among “medicines with unproven effectiveness.”

The rapid responder finding needs replication. A 40% rapid response rate with HARS dropping from 20 to 7 in 1-3 days is extraordinary. Extraordinary claims require extraordinary evidence, and n=20 is not that.

We don’t know how Selank interacts with SSRIs, SNRIs, or other Western psychiatric medications. If you’re on existing medication, this is a genuine unknown — not a known safe combination.

Quality outside Russia is inconsistent. Same issue as Semax — research-grade peptides from some vendors have tested at well below labeled potency.

What this means for you

Selank has a genuinely unique profile. An anxiolytic that also improves cognition, boosts immune function, and doesn’t cause dependence — nothing else on the market does all four.
The clinical evidence is real but limited. Head-to-head with a benzodiazepine is a meaningful test. But the studies are small and unblinded by Western standards.
The standard protocol is 14 days. If you’re a rapid responder (40% chance), you’ll know in 1-3 days. If not, give it the full two weeks before judging.
Standard dose is ~900 mcg/day intranasal (0.15% solution, 2 drops per nostril, 3x daily). This is what was studied.
Source from Russian pharmacies if possible. CosmicNootropic and RUPharma ship actual Russian pharmaceutical-grade Selank. Research-grade reconstituted peptide is a different product with variable quality.
Don’t start with NA-Selank. No evidence. Start with what was actually tested in humans.
If you’re on psychiatric medications, talk to your doctor first. This is not a suggestion — it’s a genuine safety consideration given the lack of interaction data.
It’s not a replacement for therapy. Anxiety has psychological and behavioral components that no peptide addresses. Selank, at best, is a tool — not a solution.

Sources

Zozulya A.A. et al. Efficacy and mechanisms of Selank in GAD and neurasthenia. 2008. PMID: 18454096
Rapid and slow response in GAD treatment. European Psychiatry, 2012. ScienceDirect: S0924933812752811
Medvedev V.E. et al. Selank vs. phenazepam optimization. 2014. PMID: 25176261
Medvedev V.E. et al. Selank + phenazepam combination. 2015. PMID: 26356395
Volkova A.V. et al. Selank modulates GABAergic gene expression. Frontiers in Pharmacology, 2016. PMC4757669
Kost N.V. et al. Selank inhibits enkephalin-degrading enzymes. Bioorg Khim, 2001. PMID: 11443939
Zozulya A.A. et al. Selank and enkephalin degradation. 2001. PMID: 11550013
Narkevich V.B. et al. Selank normalizes serotonin/norepinephrine under stress. 2008. PMID: 19093364
Inozemtseva L.S. et al. Selank and BDNF expression. 2008. PMID: 18841804
Solov’ev V.B. et al. Selank and carboxypeptidase modulation. 2012. PMID: 22827026
Vasil’eva E.V. et al. Selank and NMDA glycine site interaction. 2023.
Verbenko N.V., Shakina L.D. Selank for PTSD/adjustment disorder. Medical Alphabet, 2017. Link
Pogodina A.V., Nikiforova L.V. Selank for post-COVID asthenia. 2024. DOI: 10.29296/25877305-2024-05-12
Verbenko N.V., Fedorov V.V. Selank for psychogenic overeating. 2016.
Uchakina O.N. et al. fMRI comparison of Selank, Semax, and placebo. 2020. PMID: 32342318
Selank prescribing information (Vidal.ru). Link
Selank prescribing information (RLS.net). Link
GRLS registration: ЛП-No.(010951), July 2025, indefinite. Link
Selank development history. Link
Selank publications library. Link
Kolomin T.A. Dissertation: Selank gene expression in brain and spleen. 2012. DisserCat
Kasyan A.P. Dissertation: Selank as GABAergic gene modulator. 2018. DisserCat
Patent RU2318533C1: Selank for immunodeficiency correction. Link
Patent RU2629832C1: Selank hepatoprotective effects. Link
CyberLeninka: Selank biological activity and mechanisms. Link
CyberLeninka: Adaptogenic activity of Semax and Selank. Link
Semax/Selank GABA-A receptor comparison. Neurochemical Journal, 2021. Springer
Semax/Selank route of administration comparison. Neurochemical Journal, 2020. Springer